Oncopeptides is a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases. The first drug in the proprietary peptide-drug conjugate (PDC) platform, Pepaxto® (melphalan flufenamide), is approved in the US for the treatment of adult patients with RRMM. Melphalan flufenamide is evaluated in a comprehensive clinical study program including Phase 3 studies (OCEAN and LIGHTHOUSE). The second compound, OPD5, entered clinical development in Q2, 2021.